Abstract
The European Academy of Allergy and Clinical Immunology (EAACI) and the Allergic Rhinitis and its Impact on Asthma (ARIA) initiative have defined properties that should be met by oral H1 antihistamines for the treatment of allergic rhinitis. A group of experts has examined the properties of desloratadine and verified their adherence to the criteria based on high-level evidence. Publications resulting from an exhaustive bibliographical search were analysed for the methodology and level of evidence of the studies. Desloratadine pharmacodynamics, pharmacokinetics, efficacy and safety profiles perfectly meet the criteria defined by the EAACI and ARIA for oral H1 antihistamines for the treatment of allergic rhinitis. The issues highlighted by this critical analysis are common to all H1 antihistamines of the second generation.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
